Login to Your Account


Molmed: Leukemia gene therapy filing imminent

By Cormac Sheridan
Staff Writer

Tuesday, February 4, 2014
Bidding to become the second European company to secure regulatory approval for gene therapy, Molmed SpA plans to seek a conditional marketing authorization in Europe for its genetically engineered cell therapy TK treatment for high-risk acute leukemia patients in the current quarter.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription